This strongly suggests that the magnitude of BCL-2 inhibition was limited in this trial by the toxicities induced by the BCL-XL targeting of navitoclax, and treatment with a BCL-2 specific inhibitor would be expected to avoid thrombocytopenia and therefore more potently inhibit BCL-2. This evidence concerns the gene BCL2L1 and Thrombocytopenia.